贝伐珠单抗应用于非小细胞肺癌中的研究进展(6)
[27] Zhou C,Wu YL,Chen G,et al. BEYOND:A randomized,double-blind,placebo-controlled,multicenter,phase Ⅲ study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer[J]. J Clin Oncol,2015,33(19): 2197-2204.[28] Heist RS ......
您现在查看是摘要页,全文长 2689 字符。